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Back cover from Josh Boucher PhD, Staff Scientist Liaw Lab. Human retinal endothelial cells (cells that 
form the linings of blood vessels) were coated to fibrin beads and allowed to form sprouting blood 
vessels through the process of angiogenesis over 7 days.
Cover photo from Dr. Michaela Reagan’s Lab. 3D Silk Scaffold Confocal Image using stains for human 
white adipose (fat) tissue taken from liposuction samples, on silk scaffolds. Green stains are cell 
filaments, red stains are lipids, and purple/blue is autofluorescence of scaffold.
I am delighted to inform you of some of the activities and 
accomplishments of the research community at Maine 
Medical Center in 2018. Coming on the heels of several years 
of increased funding from NIH and other agencies, 2018 has 
been one of dedicated engagement by our investigators and 
scientific staff in their laboratories and in our communities 
to implement their exciting research projects.
A few examples include the clinical trial of early tracheostomy in patients who 
have suffered severe stoke now being conducted in our intensive care units under 
the leadership of David Seder, the maturation of several projects conducted by 
our junior investigators on the Center of Biomedical Research Excellence Award 
directed by Lucy Liaw, and the implementation of the Northern New England 
Clinical and Translational Research Network led by Cliff Rosen in collaboration 
with colleagues at the University of Vermont School of Medicine and the University 
of Southern Maine (graphic, p. 3).
Community engagement forms the basis of and is integral to many programs 
recently implemented, as typified by the Maine Lung Cancer Coalition and the 
Maine Cancer Genomics initiative based in our Center for Outcomes Research and 
Evaluation and led by Paul Han. It is also the hallmark of several research programs 
in our Center for Psychiatric Research, where Matt Siegel and his team are using 
biosensor technology to improve the care of autistic individuals, and where Kristen 
Woodberry is enhancing the engagement of family in the care of patients with early 
psychosis disorders. Another example highlighted herein is the dedicated work of 
Alexa Craig to develop a state-wide video communication system to optimize the 
assessment and care of newborns with brain injuries incurred during birth.
Expanding community engagement has also been the focus of our education and 
training programs. Grants received in 2017 from the American Heart Association 
and the Maine Community Foundation are now supporting the expansion of our 
summer internship program and high school education program in order to reach 
students from underserved communities in rural Maine.
I am immensely proud and appreciative of the outstanding work of these programs. 
This focus on engagement and community is helping us chart a course for how we 
can best support colleagues across MaineHealth in our newly unified health system. 
I hope you enjoy taking a closer look at the research and the individuals conducting 
this tremendous work.
Sincerely,
Don St. Germain, MD
Director & Vice President of Research
Maine Medical Center Research Institute
TABLE OF CONTENTS
Message from the Director ............................................................................................. 2
Northern New England Clinical & Translational Research Network 2018 Notables ............. 3
MMCRI at a Glance ........................................................................................................ 4
Areas of Research .......................................................................................................... 5
Cancer ................................................................................................................6-8
Neuroscience & Addiction ..................................................................................9-14
Cardiovascular & Metabolic Disease ................................................................. 15-18
Public Health ...................................................................................................19-22
Improvements in Clinical Care ......................................................................... 23-24
International Ties ............................................................................................ 25-28
Fostering Future Scientists ............................................................................... 29-30
De
ar
 F
ri
en
ds
2
Journal of Maine Medical Center, Vol. 1 [2019], Iss. 1, Art. 20
https://knowledgeconnection.mainehealth.org/jmmc/vol1/iss1/20
DOI: 10.46804/2641-2225.1025
3 MAINE MEDICAL CENTER RESEARCH INSTITUTE: 2018 YEAR IN REVIEW MAINE MEDICAL CENTER RESEARCH INSTITUTE: 2018 YEAR IN REVIEW 4
 2018 Fast Facts
In 2017 MMCRI received $20M from the National Institutes of Health to establish 
a Northern New England Clinical & Translational Research Network (NNE-CTR). 
Maine Medical Center and the University of Vermont are the lead organizations. 
Other partners include the University of Southern Maine and the Dartmouth 
CO-OP Primary Care Practice-Based Research Network. NNE-CTR’s Mission: 
Enhance the health of people in northern New England (ME, NH, VT), by fostering 
and coordinating clinical, translational and educational research activities.
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Additional funding supplement was received 
to study the impact of opioid prescribing laws.
Top 5 research topics 
participants are most 
interested in researching.
Pilot Projects Awarded
Prescription drug and opioid overdose has risen sharply over the last 
decade and is considered one of our most pressing public health issues.
Maine is among the
TOP TEN
states with the highest 
rates of opioid related 
overdose deaths
In Maine, 85% of deaths were caused by at least one 
opioid including prescription and illegal drugs during 2017
In Vermont, deaths 
involving opioids 
increased by more 
than1/3 in 2017
227
NNE-CTR participants 
from Maine, Vermont 
& New Hampshire
29 pilot program  
         letters of intent  
         submitted
5 pilot projects   
     awarded
39%
Rural health
29%
Cardiovascular
health
29%
Substance abuse
26%
Aging
26%
Cancer
2018 Sources of Research Support by Sponsor Type 
 203 Staff Members
18M Total 2018 Grant Funds
38 New Grants Awarded
200+ Clinical Trial Studies
Oncology, 
Cardiology, and 
Neurology
Top 3 Clinical Research Areas
264 Scientific Publications
12
Core Facilities with State of the Art 
Equipment and BioBank Tissue 
Repository which distributed over 
3000 biospecimens
73 Learners & Trainees in MMCRI’s Education & Training Program
 “Compositions and 
methods for treating 
inflammation and fibrosis”, 
Dr. Peter Brooks, Dr. Leif 
Oxburgh, and Jennifer Caron, 
Research Associate, Brooks Lab.
2018 Issued Patent
67.5%: Federal
20.6%: Foundation & Nonprofit
12.0%: Industry
2018 Leadership
Executive Administration
Donald St. Germain, MD 
Director & VP Research
 
Rick McAllister, MEd
Senior Director, 
Research Administration
Research Center Leadership 
Thomas Gridley, PhD
Director, Center for 
Molecular Medicine
Paul Han, MD, MA, MPH
Director, Center for Outcomes 
Research & Evaluation
 
Susan Santangelo, ScD
Director, Center for 
Psychiatric Research
 
Clifford Rosen, MD
Director, Center for Clinical & 
Translational Research
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CENTER FOR MOLECULAR MEDICINE — LEIF OXBURGH DVM, PHD 
Kidney Cancer
The Oxburgh laboratory is helping to fill the knowledge gap 
in the field of kidney cancer thanks to the Department of 
Defense Kidney Research Program award the lab received 
in September 2018. Their work focuses on modeling the 
effects of stroma on clear cell renal cell carcinoma, which is 
the most common kidney cancer. Stroma is the connective, 
functionally supportive framework of a biological tissue. The 
lab will develop a system to study the interactions between 
cancer cells and the normal cells that surround them. The 
project will analyze the effect of the cellular environment 
within the kidney on the aggressiveness of tumors. In order to 
understand this better, researchers will combine tumor cells 
with normal cells from kidney cancer patients and tumors of 
differing aggressiveness. A promising practical result of this 
work will be a means to model tumors from individual cancer 
patients. This may be an important tool in personalized 
medicine as it has the potential to enable testing of anti-
cancer drug activities at the level of the individual patient.
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NEUROSCIENCE & ADDICTION
CARDIOVASCULAR & METABOLIC DISEASE
PUBLIC HEALTH
IMPROVEMENTS IN CLINICAL CARE
INTERNATIONAL TIES
FOSTERING FUTURE SCIENTISTS
Models of renal cell carcinoma made in the Oxburgh lab replicate what is found in human patients: Human 
cancer tissue, on the left, shows unique patterning between stroma (red) and cancer (green). This patterning is 
mirrored in lab-made tumor models on right. Cancer cell lines (green) pattern similarly with stromal cell lines 
(red) when grown in scaffolds made from silk (blue).
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FRANKLIN COMMUNITY HEALTH
NETWORK, FARMINGTON
LINCOLNHEALTH, DAMARISCOTTA
AND BOOTHBAY HARBOR
WALDO COUNTY GENERAL
HOSPITAL, BELFAST
PEN BAY MEDICAL CENTER,
 ROCKPORT
MID COAST HOSPITAL,
BRUNSWICK
MAINE MEDICAL CENTER,
PORTLAND
SOUTHERN MAINE
HEALTH CARE, BIDDEFORD
WESTERN MAINE HEALTH,
NORWAY
MEMORIAL HOSPITAL,
NORTH CONWAY, NH
MAINEGENERAL MEDICAL
CENTER HAROLD ALFOND CENTER
FOR CANCER CARE, AUGUSTA
ST. MARY’S REGIONAL
MEDICAL CENTER, LEWISTON
CENTER FOR OUTCOMES RESEARCH & EVALUATION 
Maine Cancer Genomics Initiative
MAINE HEALTH CANCER CARE NETWORK EXPANDING 
Research Connections: MaineHealth Cancer Care Network
The Center for Outcomes Research and Evaluation 
(CORE) is in the second year of a five-year initiative to lead 
the outcomes evaluation component of the Maine Cancer 
Genomics Initiative (MCGI). Supported by the Harold 
Alfond Foundation, the MCGI is a unique collaboration 
between research and clinical institutions. CORE Principal 
Investigator Dr. Paul Han and Drs. Jens Reuter & Andrey 
Antov from the MCGI team at Jackson Laboratory, have 
partnered to study the implementation of tumor genomic 
testing and downstream outcomes that will inform the 
implementation of precision medicine in oncology. This 
work will also develop a sustainable research-healthcare 
system partnership model.
The MCGI is on its way to reaching the goal of providing 
tumor genomic testing to 1,800 Mainers. Analyses will look 
at provider and patient surveys and qualitative interviews. 
The data provide information on oncologists’ use, confidence, 
attitudes, and perceived barriers to implementing genomic 
tumor testing, as well as patients’ beliefs and attitudes 
towards the role tumor genomic tumor testing plays in their 
health care journey. Together, these data play a vital role in 
helping us understand how to implement tumor genomic 
testing in community oncology settings, and shedding light 
on physician and patient knowledge, attitudes and beliefs 
towards this new technology.
Cancer is the most common cause of death across our communities, and hundreds of caregivers from across the MaineHealth 
system have come together to focus their efforts on prevention and treatment. The MaineHealth Cancer Care Network 
(MHCCN) was launched in 2014 to provide comprehensive coordinated cancer care to patients across Maine. This network, 
which includes 11 MaineHealth partner hospitals and organizations, offers a robust research arm, in partnership with Maine 
Medical Center Research Institute and the Jackson Laboratory Cancer Center in Bar Harbor. 
The network, supported by a grant from The Harold Alfond Foundation, not only provides 
treatment, but prevention and education initiatives as well.
In 2018 the MHCCN nearly doubled its number of enrolling trials, expanded its 
National Cancer Institute Network Group, continued to build Maine Medical Center 
based trails in specialty areas, increased its research staff by sixty percent, and 
established an Oncology Protocol Review Committee.
For more information about MHCCN 
visit: mainehealth.org/cancer
M C G I  H I G H L I G H T S  2 0 1 8
number of 
enrolled patients494
participating 
oncologists59
genomic 
tumor boards18
participating 
practices15
CANCER
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NEUROSCIENCE & ADDICTION
CENTER FOR MOLECULAR MEDICINE — ARTURO HERNANDEZ, PHD 
Neuroendocrinology & Metabolism
CENTER FOR PSYCHIATRIC RESEARCH — MATT SIEGEL, MD 
Research Funding for Novel Biosensors will Help Parents of Children with Autism
The Hernandez laboratory successfully competed for a 5-year renewal of their NIH 
research grant entitled “Transgenerational Epigenetic Programming of the Thyroid 
axis”, funded by the National Institute of Diabetes, Digestive and Kidney Diseases. 
The project aims to delineate how abnormal exposure to thyroid hormones during 
development influences the endocrine function and metabolic programming in future 
generations via inherited but non-genetic mechanisms. This research can shed light on 
why some individuals are more likely to be susceptible to obesity and metabolic disease, 
based on differences in their hormonal systems.
In October 2018, the Simons Foundation of New York, NY 
and the Nancy Lurie Marks Family Foundation of Wellesley, 
MA awarded Maine Medical Center Research Institute 
(MMCRI) and Maine Behavioral Healthcare (MBH) a $3.1 
million grant to study the use of wearable biosensors to 
provide real-time warnings of impending aggression in 
children with autism. Dr. Matthew Siegel, a Faculty Scientist 
at MMCRI and VP of Medical Affairs for Development 
Disorders at MBH is the Principal Investigator for the project. 
The goal is that these watch-like devices will enable clinicians 
and caregivers to predict challenging behaviors in children 
with autism and create a new opportunity to intervene and 
prevent problems before they occur. Current approaches 
to behavioral problems in autism have primarily focused 
on what happens after the behavior occurs. This three-year 
clinical study will investigate whether physiology signals 
such as heart rate and sweating can indicate the probability 
of an impending aggressive episode, and allow people in the 
environment to receive a warning. 
This research study is being performed through the 
Autism & Developmental Disorders Inpatient Research 
Collaborative (ADDIRC), a research network of specialized 
child psychiatric hospital units that serve children and 
adolescents with autism and other developmental disorders. 
The ADDIRC was founded in 2013 by Dr. Siegel and is 
coordinated by MMCRI/MBH.
Imagine the possibilities for prevention and a family’s 
quality of life if we can accurately predict that one of 
these behaviors will likely happen in the next 2 minutes. 
Suddenly, we are able to know when things are not 
going well, provide coping strategies, and increase 
safety. …Put simply, this is a potentially transformative 
approach to serious problem behaviors in autism.
— Dr. Matthew Siegel 
Faculty Scientist , MMCRI
VP of Medical Affairs for Development Disorders, MBH
Dr. Siegel wearing a biosensor
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Woodberry Research Team (L to R):  
Kate Powers, Research Assistant, Dr. Woodberry, and Anna Cloutier, Research Nurse Coordinator
CENTER FOR PSYCHIATRIC RESEARCH — KRISTEN WOODBERRY, MSW, PHD 
Understanding Early Psychosis in Youth
NORTHERN NEW ENGLAND CLINICAL & TRANSLATIONAL RESEARCH NETWORK RECEIVES 
ADDITIONAL FUNDING IN 2018 
Supporting Public Health Initiative to Fight the Opioid Crisis in rural New EnglandSeventy-five percent of adult mental illnesses emerge by 
age 24, with the majority appearing between ages 15 and 
24. Given increasing evidence for the benefits of early 
intervention, identifying predictors and indicators of 
emerging mental illness is a high public health priority. In 
2018, The National Institute of Mental Health (NIMH) 
awarded an Exploratory/Developmental Research Grant 
to new Faculty Scientist Kristen Woodberry, MSW, PhD to 
collect dynamic data in adolescents and young adults at risk 
for or in the early stages of severe mental illness. The project 
aims to better understand the interaction of emerging 
symptoms and social context over time. 
Using a smartphone app, the Daily Life Study is collecting 6 
mood and symptom reports a day for 21 days in 60 Boston 
and Portland area youth ages 15-25. By comparing the daily 
reports of those with and without psychotic symptoms, Dr. 
Woodberry hopes to identify whether youth with psychotic 
symptoms experience greater mood variability than their 
non-psychotic peers, and whether mood variability predicts 
psychotic symptoms or thoughts of self-harm. This project 
is a preliminary step in a line of research examining the 
interaction of mood and psychosis and identifying patterns 
or sequences that can predict critical events such as suicide 
attempts during the early course of major mental illness. 
Early course symptom dynamics are also expected to inform 
our understanding of illness progression and help develop 
novel interventions to interrupt pathological sequences and 
improve functional outcomes.
This project is one arm of a broader effort to build on Maine 
Medical Center’s leadership role in Early Intervention in 
Psychosis, initiated through the nationally-recognized 
Portland Identification and Early Referral (PIER) program, 
pioneered by Dr. William McFarland. Dr Woodberry is 
working closely with PIER Clinical Director, Sarah Lynch, 
Drs. Doug Robbins and Susan Santangelo, and Maine Health 
leadership to build a regional Center of Excellence focused 
on early psychosis research, training, and coordinated 
specialty care.
In 2016, Maine and Vermont responded to the opioid crisis 
with legislation regarding opioid prescribing guidelines and 
requirements for prescription drug monitoring programs. The 
goal was to reduce access to opioids and make it more difficult 
for patients to obtain prescriptions from multiple providers. 
Through supplemental NIH funding received in 2018 by the 
Northern New England Clinical and Translational Research 
Network (NNE-CTR), Maine Medical Center Research 
Institute (MMCRI) and its partnering institution, the 
University of Vermont (UVM), are now studying the impact 
that stricter opioid prescribing laws have had on population 
health in northern New England.
Dr. Kathleen Fairfield of MMCRI and the Department 
of Medicine at Maine Medical Center and Drs. Valerie 
Harder and Timothy Plante of UVM, will analyze whether 
that legislation has successfully led to a decrease in opioid-
related overdoses, hospitalizations and other medical 
events and whether there were unintended consequences, 
such as patients suffering from substance use disorders 
turning to the illegal use of heroin instead. The team also 
will analyze whether outcomes are different for various 
patient demographics, such as whether they live in a rural 
or urban area.
While this grant provides additional funds for the NNE-
CTR to focus on a specific issue of the opioid crisis on 
our community, the Network continues to fund pilot 
projects that focus on the other aspects of the opioid crisis, 
highlighted on the next page.
This research provides us the opportunity to study the impact of state laws regarding 
opioid prescribing while engaging with a wide variety of community members in real 
time. We hope this work will help inform clinical care of patients, community-based 
interventions, future policy changes and additional research.
— Dr. Kathleen Fairfield 
MMCRI’s Lead Investigator on the NNE-CTR’s Opioid Grant
Dr. Kathleen Fairfield
NEUROSCIENCE & ADDICTION
7
et al.: 2018 Year in Review - Maine Medical Center Research Institute
Published by MaineHealth Knowledge Connection, 2019
13 MAINE MEDICAL CENTER RESEARCH INSTITUTE: 2018 YEAR IN REVIEW MAINE MEDICAL CENTER RESEARCH INSTITUTE: 2018 YEAR IN REVIEW 14
Opioid prescription can be extremely addictive and is associated with substantial morbidity and mortality. Receipt 
of prescription opioids is associated with a 3 to 4-fold increase in fracture risk. This is concerning because opioids 
are often prescribed for fractures and metastatic cancer. Though opioids are associated with an increased risk of 
bone fracture, the mechanisms of this risk are unclear. Dr. Katherine Motyl was awarded a pilot project in 2018 
through the Northern New England Clinical & Translational Research Network (NNE-CTR) to study direct and 
indirect mechanisms of opioid –induced bone loss. Dr. Motyl will test if bone loss from opioids is due to elevated 
sympathetic nervous system output to bone, as well as test to see if opioids impact bone directly through interactions 
with osteoclasts (a large bone cell that absorbs bone tissue during growth and healing).This work will fine tune 
treatment and prevention strategies for patients who are prescribed opioids.
NORTHERN NEW ENGLAND CLINICAL & TRANSLATIONAL RESEARCH NETWORK — 
REDUCING OPIOID ABUSE 
Katherine Motyl, PhD: Direct and indirect mechanisms of opioid-induced bone loss
  
 
Kinna Thakarar, DO, MPH: Rural Harm Reduction Access and Regional Trends (Rural HeART)
Dr. Thakarar’s NNE-CTR pilot project grant seeks to examine access to harm reduction services among people who 
inject drugs and are hospitalized with infectious complications. With increasing incidence of hepatitis B, hepatitis C, 
and ineffective endocarditis in Maine over recent years, there are particular concerns about high-risk persons who 
inject drugs in rural areas being able to access harm reduction services such as syringe site programs, which have 
been shown to effectively reduce the transmission of infections, deliver overdose prevention and education, increase 
vaccinations, and facilitate referrals for medication for addiction treatment.
Although the infectious complications of injection drug use (IDU) are serious and costly, relatively little attention 
has been paid to characterizing the epidemiology of IDU-associated infectious complications or utilization of harm 
reduction services. Results of this study will help inform future interventions to improve access to harm reduction 
services in Maine and potentially other areas of northern New England.
For more information about the NNE-CTR visit: nne-ctr.net
Dr. Katherine Motyl
NEUROSCIENCE & ADDICTION
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CENTER FOR MOLECULAR MEDICINE — LUCY LIAW, PHD 
Investigating the Causes of Cardiovascular disease
CENTER FOR MOLECULAR MEDICINE – ILKA PINZ, PHD AND DOUG SAWYER, MD, PHD 
Nutrition’s Impact on Cardiovascular Disease
Why is obesity a risk factor for cardiovascular disease? This is one of the questions being addressed in a project in the Liaw 
laboratory that was funded by the National Heart, Lung, and Blood Institute at the NIH in July 2018. The study focuses 
on perivascular adipose tissue, which surrounds major blood vessels in the body. This adipose tissue contributes to the 
cellular neighborhood of the circulatory system, and changes during obesity and metabolic disease. This project includes 
collaborations between basic scientists and vascular surgeons to understand differences in this adipose tissue in patients 
with varying levels of cardiovascular disease. Studies will address the interesting scientific questions of how the adipose 
tissue surrounding vessels can influence or protect from disease. Because cardiovascular disease and obesity are two of the 
most prevalent health issues, this research will have significant impact for a majority of the country’s population. The goal 
is to understand what causes cardiovascular disease so that it can be prevented or treated more effectively.
Diet plays an important part in our overall health and in 
disease prevention. However there is little research on the 
impact of specific diets in patients with type 2 diabetes 
mellitus (T2DM) and with ischemic heart disease (the term 
given to heart problems caused by narrowed heart arteries). 
Patients with T2DM and ischemic heart disease have 
substantially higher chances to develop certain illnesses than 
those without T2DM, and more frequently develop heart 
failure. Strategies to improve glycemic control with insulin 
or drugs taken orally have not impacted cardiovascular 
disease and mortality outcomes in T2DM patients with 
known heart disease. Our research in mice and humans 
has shown that a western style diet with a high amount of 
saturated fat impairs not only insulin but also neuregulin 
(NRG) signaling in cardiac muscle cells. Insulin and NRG 
signaling are important not only for the metabolism of sugar, 
but also for survival signals in a stressed heart. Drs. Ilka Pinz 
and Douglas Sawyer received a pilot project award from 
MMCRI’s Center of Biomedical Excellence in Metabolic 
Networks in late 2018 to study nutrition’s impact on type 
2 diabetic patients with heart disease. They will test how 
short-term Mediterranean diet consumption changes the fat 
composition of cardiac muscle cells and thus protects insulin 
and NRG signaling in humans. This work will increase 
our understanding of the molecular pathology that dietary 
choices influence and will help to develop new treatments 
for type 2 diabetic patients with heart disease.
CARDIOVASCULAR & METABOLIC DISEASE
Progenitor cells surrounding blood vessels can be collected 
from patients with cardiovascular disease and studied in the 
lab for their ability to become adipocytes, or fat cells. Image 
shows human progenitor cells grown as three dimensional 
aggregates and programmed to become adipocytes. The 
resulting “adipospheres” show green staining of lipids, red 
staining of perilipin1, a lipid droplet-associated protein, 
and blue stained nuclei. This adiposphere model allows us 
to better mimic human fat tissue in the research lab.
Artherosclerotic Plaque
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NORTHERN NEW ENGLAND CLINICAL & TRANSLATIONAL RESEARCH NETWORK 
Teresa May, DO: Opioid and Non-opioid Related Cardiac Arrest Outcomes in Northern New England
  
Research in Metabolic Disease
Cardiac arrest is the third leading cause of death in 
North America, with great variation in survival rates in 
different regions of the U.S. These differences may be 
due to factors related to the patients, emergency medical 
services, or hospitals. Dr. May was awarded a pilot project 
in 2018 through the Northern New England Clinical & 
Translational Research Network to study these factors across 
the states of Maine, New Hampshire and Vermont. Other 
factors that may influence patient outcomes are whether 
the cardiac arrest is related to opioid use, and whether the 
patient suffering the arrest lives in a rural or more populated 
region. Dr. May will study variations in the provision of 
health services and patient outcomes for both opioid related 
and non-opioid related cardiac arrest, broken down by 
geographic region throughout Maine, New Hampshire and 
Vermont. Dr. May’s work will help define the geographic 
barriers to cardiac arrest care throughout Northern New 
England, and should help impact care for cardiac arrest 
patients in the current opioid epidemic, affording the 
opportunity to improve clinical outcomes in the region in 
both opioid related and non-opioid related cardiac arrest.
For more information about the NNE-CTR visit: nne-ctr.net
Dr. Cliff Rosen
CARDIOVASCULAR & METABOLIC DISEASE
Publication in scientific journals is a key way that scientists share their results with the scientific community. MMCRI 
investigators had 264 publications in 2018. Two of those reported exciting breakthroughs in major scientific publications 
and are highlighted below. 
Cliff Rosen, MD, Director of the Center for Clinical & 
Translational Research, in collaboration with scientists at 
the Dana-Farber Cancer Institute and other organizations, 
has discovered that irisin, a hormone released by muscles 
during exercise, directly acts on key regulatory cells that 
control the breakdown and formation of bone, raising the 
prospect of new treatments for bone-thinning disorders like 
osteoporosis. This research was published in December 2018 
in the journal Cell.
 
Aaron Brown, PhD, reported in the journal Cell Reports 
(December 2018) that an anti-diabetic fat generated in the lab 
could be used to help develop new drugs and treatments for 
diabetic and obese patients. For example, long-term, this fat 
could be transplanted into patients to burn calories or secrete 
anti-diabetic molecules that alleviate the disease. Researchers 
in Dr. Brown’s lab plan to first test the anti-diabetic fat by 
transplanting it in mouse models of obesity and diabetes prior 
to human studies. The work was funded in large part through 
MMCRI’s COBRE award entitled “Mesenchymal and Neural 
Regulation of Metabolic Networks.”
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PUBLIC HEALTH
VECTOR-BORNE DISEASE LABORATORY 
A Surge in Anaplasmosis
  
Earlier Diagnosis of Lyme Disease
Cases of anaplasmosis, a tick borne infection that is particularly severe in the elderly, dramatically increased in Maine over 
the past 5 years (Figure 1). With the assistance of a private donation, the Vector-borne Disease Laboratory team launched 
a project to determine if risk of infection varies geographically in Maine by testing ticks collected from northern and 
southern tiers of the state. In addition, parallel research investigated patterns of disease diagnosis and the frequency of 
hospitalization, in order to gain a better understanding of the causes of the observed increase in cases. The goal is that 
this knowledge will lead to more focused public health approaches to the prevention of anaplasmosis.
Dr. Robert Smith and Research Associate Susan Elias began a collaboration with the company MicroBPlex on a National 
Institutes of Health funded project in 2018 to examine the effectiveness of a diagnostic test to aid in the detection of early 
Lyme disease in patients in southern Maine. This project will expand in 2019 to involve three geographic areas in Maine: 
Greater Portland, with Maine Medical Center Research Institute as coordinator; Mid-coast Maine with a study center at Pen 
Bay Medical Center; and southern Maine at Southern Maine Health Care. A clinical site associated with Johns Hopkins 
Medical Center in Baltimore is also a partner. This novel approach to diagnosis may lead to earlier confirmation of Lyme 
disease, as well as the possibility of distinguishing past from current infection. The linkage of several different clinical sites 
in Maine for studies of tick borne disease is a promising prototype for future diagnostic and treatment trials.
A Focus on Disease Carrying Mosquitos
With support from a Maine Centers for Disease Control 
grant, Research Assistant Margret Welch and vector 
ecologist Charles Lubelczyk established an insectary in 
cooperation with the University of Southern Maine in 
Gorham to test the development of pesticide resistance 
in native species of mosquitoes that are of medical or 
veterinary importance. Testing for pesticide susceptibility 
will include vector mosquitoes from across geographic 
regions in Maine. This movement of a new mosquito 
species capable of transmitting disease in Maine, coupled 
with the recognition of the mosquito-transmitted virus 
(Jamestown Canyon virus), is of great concern, and the lab’s 
mosquito surveillance program, guided by Lubelczyk and 
Field Biologist Libby Henderson, is integrating this study 
with other studies on the effectiveness of chemical controls 
and public and veterinary risks of mosquito-borne disease.
Chuck Lubelczyk, Vector Ecologist 
for MMCRI, completing field work.
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CENTER FOR OUTCOMES RESEARCH & EVALUATION 
Maine Lung Cancer Coalition: a statewide collaboration
NORTHERN NEW ENGLAND CLINICAL & TRANSLATIONAL RESEARCH NETWORK 
Improving Health in Rural Communities across New England 
The Maine Lung Cancer Coalition (MLCC) is a 4-year 
statewide, multi-institution, multi-disciplinary initiative 
begun in August 2016, with funding from the Bristol Myers 
Squibb Foundation, with the goals of improving lung 
cancer prevention, early detection, stakeholder education, 
and research and data analytics for a better understanding 
of lung cancer determinants, disparities, and outcomes. 
MMCRI is the lead institution for the Coalition, which 
is led by Dr. Paul Han (Principal Investigator), Dr. Neil 
Korsen (Co-PI), and Leo Waterston (Project Director). The 
MLCC brings together diverse stakeholders across Maine 
to work together to reduce suffering and death from lung 
cancer, with a special focus on vulnerable rural populations 
with limited access to health care.
The MLCC, through its partner the MaineHealth Center 
for Tobacco Independence, received a grant for $30,000 in 
2018 from Anthem Blue Cross and Blue Shield Foundation 
Over 60 percent of Maine’s population lives in a rural 
area and Maine is the 2nd most rural state in the nation 
(based on population density). The Northern New England 
Clinical and Translational Research Network (NNE-CTR) 
was established in July 2017 to enhance the health of people 
in northern New England (ME, NH, VT) by fostering 
and coordinating clinical, translational and educational 
research activities.
One key goal of the NNE-CTR is to bring clinical and 
translational research opportunities to rural communities 
in Maine. Dr. Neil Korsen is leading this effort in Maine 
through the Rural Health Research and Delivery Core, 
which has begun to build partnerships with rural clinicians 
and practices to increase their participation in clinical 
trials. Dr. Korsen has also worked with rural clinicians 
to help them develop their own research ideas, providing 
technical assistance as needed.
The Rural Core is working closely with two rural 
communities in Maine: Western Maine Health in the 
Oxford County area and Pen Bay Medical Center on the 
Maine coast in Rockport. To connect the community with 
clinicians and researchers in the Oxford County Area, the 
Rural Core sponsored a community symposium: Building 
Partnerships for Rural Health Research in June 2018. The 
event was attended by 40 participants including researchers, 
clinicians and community members. The Rural Core is 
now working with a subset of symposium participants to 
develop a research project targeting individuals impacted 
by Adverse Childhood Experiences.
to integrate evidence-based smoking cessation treatment 
into lung cancer screening. The project targets older, heavy 
smokers residing in rural Maine who are at high lung cancer 
risk and have been referred for lung cancer screening with 
low-dose CAT or CT scan (LDCT). 
Other highlights in 2018 include launching pilot projects 
to generate evidence on ways of improving access to lung 
cancer prevention and screening services to populations 
in Maine. These projects include studies of the geographic 
burden of lung cancer and utilization of lung cancer 
screening and treatment services; community members’ 
perceptions and attitudes regarding lung cancer risk and 
prevention; use of telemedicine to conduct shared decision 
making consultations for lung cancer screening; and a 
statewide survey of primary care physicians’ knowledge 
and attitudes regarding lung cancer screening.
For more information about the MLCC, visit: mainelungcancercoalition.org For more information on the NNE-CTR and the Rural Core, visit: nne-ctr.net
Rural Core Team (L to R): Project Manager, Lisbeth Wierda, 
MPH, Dr. Korsen, and Research Navigator, Kerri Barton, MPH.
PUBLIC HEALTH
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IMPROVEMENTS IN CLINICAL CARE
The Cystic Fibrosis Foundation Awards 
MMC $1.1M for Multi-Center Study 
In July of 2018, the Cystic Fibrosis Foundation awarded 
Maine Medical Center $1.1M for a multi-center study 
investigating complications associated with use of midline 
and peripherally inserted central venous catheters (PICCs) in 
Cystic Fibrosis (CF) patients. Cystic Fibrosis is a progressive, 
genetic disease that causes lung infections which often 
require repeated courses of intravenous antibiotics through 
PICCs or midline catheters. A range of adverse events 
such as clots, infection and permanent distortion of blood 
vessels can arise from use of these catheters. Identifying 
risk factors for these complications should help healthcare 
providers prevent injury and improve overall outcomes in 
this vulnerable population. Dr. Jonathan Zuckerman, Maine 
Medical Center and Dr. Alex Gifford, Dartmouth-Hitchcock 
Medical Center, are the lead Principal Investigators for 
the project. “To date, no multicenter study has carefully 
investigated these complications in a large, diverse group of 
adult and pediatric CF patients. We are excited to leverage 
the resources and talents available through Maine Medical 
Center Research Institute to coordinate such a large effort,” 
said Dr. Zuckerman. The study will include 10 sites across 
the United States and span 3 years.
For more information on this study, visit: picccf.org
Dr. David Seder, MD: Stroke Study 
Continues to Make Progress
SETPOINT2 is an international, multi-site clinical trial 
to improve outcomes for patients who have suffered a 
severe stroke by assessing the best timing of tracheostomies. 
Heading this study is Dr. David Seder, the U.S. Principal 
Investigator (Maine Medical Center), along with Dr. Julian 
Bösel, the German Principal Investigator (Kassel University 
Hospital). SETPOINT2 stands for Stroke-Related Early 
Tracheostomy vs Prolonged Orotracheal Intubation in 
Neurocritcal Care Trial2.
The study is entering its third year, and 2018 marked 
considerable growth with patient enrollment and new 
site activations. The SETPOINT2 findings could benefit 
patients because the timing of a tracheostomy may affect 
the amount of sedating medications that is required, and 
could affect brain recovery and the body’s ability to return 
to pre-stroke activities. Preliminary studies suggest it could 
be beneficial to perform a reversible tracheostomy procedure 
earlier than is usually done after severe stroke (within the 
first 5 days), as opposed to delaying more than 10 days before 
performing the procedure.
For more information on this study, visit: setpoint2.org
Alexa Craig, MD: Improving Neonatal Care
Dr. Craig, Neonatal and Pediatric Neurologist, was awarded 
a pilot project in 2018 through the Northern New England 
Clinical and Translational Research Network (NNE-CTR) 
to study ways to improve the detection of and treatment 
for neonatal encephalopathy in rural areas. Neonatal 
encephalopathy is a type of brain injury that can occur in 
newborn infants due to lack of oxygen and blood flow to the 
brain around the time of birth.
Therapeutic hypothermia is the only known treatment for 
neonatal encephalopathy; this involves placing the baby on 
a cooling blanket that maintains a temperature of 91 degrees 
Fahrenheit for 72 hours followed by 12 hours of rewarming. 
The baby is monitored in an intensive care unit during this 
treatment and magnetic resonance imaging is then performed 
to determine presence or absence of brain injury. 
 
To combat these challenges, Dr. Craig developed her 
NNE-CTR pilot study to employ a telemedicine consult, a 
three-way, real-time interactive communication via video 
between the rural physician, the neonatologist at MMC 
and Dr. Craig. For infants and their families, this means 
faster diagnosis and treatment via a live consultation, thereby 
improving their chances of a better outcome or avoiding 
unnecessary treatment. Dr. Craig will assess the results of 
her pilot project in the next year to determine if the real-
time consultations successfully decrease the time to initiate 
therapeutic hypothermia.
A peripherally inserted central 
venous catheters (PICC) Close Up
Dr. David Seder
One of the clinical challenges of this treatment is that it must be started within the first six hours of life, and earlier 
treatment is known to be associated with improved outcomes. For the 75 percent of infants treated with hypothermia 
who are born in rural Maine hospitals, recognizing neonatal encephalopathy and getting the baby cooled quickly 
are particular challenges, especially for providers in rural locations who do not see these babies all that often.
— Dr. Alexa Craig
Neonatal and Pediatric Neurologist
For more information about the NNE-CTR visit: nne-ctr.net
Dr. Alexa Craig
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Susan Miesfeldt, MD: Improving Palliative 
Care in Tanzania
Nearly 80% of those diagnosed with cancer in Tanzania 
die from their disease due to limited numbers of 
adequately resourced cancer care facilities. As a result, 
access to effective palliative care is a critical public 
health priority in Tanzania, and Africa as a whole, and 
the need for innovative community-based solutions is 
highly recognized. Palliative care in the cancer patient 
is focused on improving quality of life by relieving pain 
and other distressing symptoms as well as addressing 
emotional, social and spiritual needs. Although there 
are few palliative care specialists in Tanzania, mobile 
technology holds promise in improving community-
based access to care by linking the limited pool of 
specialists with patients, caregivers, and local health workers. Dr. Susan Miesfeldt, Clinician Investigator at MMCRI, 
received funding from the National Institutes of Health Fogarty International Center in late 2017, to develop an 
innovative community-based mobile health solution to a limited palliative care workforce. The overall goal is to develop 
and test a mobile phone-based symptom assessment/control communication application (m-Palliative Care Link; 
mPCL) that remotely facilitates symptom self-reporting among late-stage cancer patients and communication between 
patients, local health workers and specialists, aimed at effective information exchange and reduced symptom burden. 
In the first year of funding, partnering with US-based software engineers and Tanzanian researchers and clinicians, 
the team has completed mPCL development and usability testing. In the second and final year of funding, they will 
complete an mPCL pilot test among 45 Tanzanian late-stage cancer patients. By working with existing personnel and 
technology, this work promises to result in a sustainable and scalable means to support high quality, patient-centered 
symptom assessment and control in Tanzania and other low-resource countries, relevant not only to cancer patients 
but other chronic diseases patients as well.
INTERNATIONAL TIES
Scot Remick, MD: Developing Training & 
Research Infrastructure in Kenya
The burdens of cancer and cerebrovascular disease --a 
group of conditions that can lead to a cerebrovascular 
event, such as a stroke-- are major causes of morbidity 
and mortality in Kenya. Kenya’s limited research 
infrastructure and significant scarcity of doctors to 
address these increasing chronic threats are a major 
challenge to public health. With funding by the National 
Institutes of Health Fogarty International Center, an 
international team of highly interactive and experienced 
investigators is addressing these issues by developing 
vital training and research infrastructure, evidence-
based approaches for intervention, and public health 
policy. The team, led by Dr. Scot Remick, Chief of 
MaineHealth Oncology & Clinical Investigator at Maine Medical Center Research Institute, includes senior Kenyan 
collaborator Dr. Walter Mwanda, University of Nairobi; Ms. Anne Korir and Dr. Lydia Kaduka at the Nairobi Cancer 
Registry and Kenya Medical Research Institute in Nairobi; and Dr. Patrick Loehrer at Indiana University and his Kenyan 
collaborator Dr. Nathan Buziba, Moi University in Eldoret. This diverse team is working to develop sustainable research 
capacity for cancer and cerebrovascular disease control in Kenya across the lifespan. 
To date the team has trained 8 stroke {Non-Communicable Disease (NCDs)] registrars; successfully launched and 
completed the first-ever NCD Stroke Registry in Sub-Saharan Africa; supported one post-doctoral training and PhD 
candidate for health policy in cerebrovascular disease and cancer epidemiology respectively; supported five early-career 
Kenyan trainees in the Department of Hematology and Blood Transfusion to satisfy requirements for three Pathology 
and two Clinical Cytology masters degrees; trained two physicians in palliative care medicine with a focus on end-of-life 
care in the pediatric setting; and sponsored a workshop that trained more than 30 healthcare professionals in pediatric 
palliative and end-of-life care. Dr. Remick and his colleagues hope to compete for successor NIH Fogarty International 
Center funding to build on the success of the current project.
Dr. Miesfeldt and research team during usability 
testing.
Pediatric Palliative Care and End of Life Training 
Workshop July 2018, Kenyatta National Hospital, 
Nairobi, Kenya
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INTERNATIONAL TIES
Research Goes Global
Research is a global endeavor at Maine Medical Center 
Research Institute and the Institute has welcomed 
research scholars from other countries for many years. 
In September two scholars from Lund University 
School of Medicine in Sweden came to participate 
in a research collaboration with physician scientists 
in Critical Care Medicine at Maine Medical Center. 
Ameldina Bilkanovic and Zana Haxhija, who are in 
their final year of medical school, traveled to Portland 
to collaborate for three months with David Seder, MD, 
and the neurocritical care research team on a project 
related to the International Cardiac Arrest Registry 
Database. Zana and Ameldina also worked with Sarah 
Peterson, MD, PhD in the Sawyer Ryzhov Lab on basic 
science and translational research. Biostatistician Lee 
Lucas RN, PhD from the Center for Outcomes Research 
and Evaluation worked with Zana and Ameldina on the 
biostatistical elements of the project. The students had 
a robust research experience and felt that their time 
in the U.S. was well-spent. “We gained so much! We 
learned a lot about our project and a lot about ourselves, 
living away from home. Combining research and rounds 
helped us to see how healthcare works here in the U.S.,” 
said Zana. “It helped me to confirm that critical care is 
an area I would like to go into,” says Ameldina. Zana and 
Ameldina worked on two manuscripts during their time 
at MMC and will present their research at their home 
university in Sweden upon their return.
VISITING SCHOLARS
Ashwani Gupta, PhD Postdoctoral Fellow — 
Oxburgh Lab 
Ashwani came to MMCRI from Sanjay Gandhi 
Postgraduate Institute of Medical Sciences, Lucknow, 
Uttar Pradesh, India. He joined the Oxburgh Lab in 
2016 to focus on kidney research in an area that may be 
instrumental in kidney repair or replacement. Specifically 
the Oxburgh Lab is doing research to make kidney tissue 
from skin derived cells and testing their functionality. The 
preliminary data looks promising and Ashwani is looking 
forward to continuing his work in kidney research.
Yosta Vegting — Rosen Lab
Yosta is a medical student from the University of Amsterdam 
in the Netherlands. She came to MMCRI in 2018 to 
participate in research collaboration before graduating. Yosta 
is in the Rosen Lab doing research on a newly discovered 
hormone called irisin. Irisin is made by muscles when 
exercising and could help to build our knowledge as to why 
exercising is healthy. Yosta is looking forward to using the 
research techniques learned at MMCRI to pursue her PhD.
Zana Haxhija (left) and Ameldina Bilkanovic (right) Yosta Vegting
Ashwani Gupta, PhD
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FOSTERING FUTURE SCIENTISTS
Advancing Maine’s High 
School Science Curriculum 
In June 2018, Maine Medical Center Research Institute 
was awarded $10K from the Celia Lipton Farris & Victor 
W. Farris Foundation Home Community of the Maine 
Community Foundation to expand its current high school 
program, called NextGen, to other high schools throughout 
Maine. The grant funding is being used to create a hands-
on science and research curriculum pilot program for high 
school classrooms.
 
MMCRI currently offers a high school education program 
to a small number of Maine schools. Students and teachers 
travel to MMCRI once a month for a seven session-program 
to learn about biomedical research through experiential 
learning activities. The program created with this grant 
funding will allow schools to benefit from the MMCRI 
program for less money and with less travel.
 
MMCRI researchers and staff are working collaboratively 
with several educators and using lessons from the current 
high school program to create portable kits for classrooms 
which will include a detailed on-line science curriculum 
and videos. 
MMCRI Summer Student Research Program Expands Opportunities for Underrepresented Students
This past summer MMCRI’s Summer Student Research Program (SSRP) had a record number of summer interns. This 
was in part due to an undergraduate research award in 2018 from the American Heart Association, designed to enhance 
the diversity of college student research interns at Maine Medical Center. There are many opportunities in Maine to reach 
students from groups that are underrepresented in STEM careers, which is the focus of this effort. In Maine there are a 
large number of students from rural and economically disadvantaged communities, a growing immigrant population, and 
a state university system where approximately one-half of the students are first generation college students. In an attempt to 
measure diversity, students were provided with an optional demographic information collection sheet. Data was also analyzed 
to determine if students were from a rural Maine county, from one that has a higher than state average of free or reduced 
lunch, or from one in which the population has a higher than state average of people with a high school diploma or less. 
Moving forward, the goal will be to develop proactive measures to continue to help identify students from underrepresented 
groups, expanding opportunities and engagement for all SRRP students.
2018 Summer Student Research Program Participants
Developing and giving access to this curriculum is 
exciting for us, as are the possibilities that lie ahead 
for this program. Careers in science and technology 
are high growth areas in Maine, and programs like 
these expose and engage students early.
— Lucy Liaw, PhD
MMCRI Senior Scientist 
Director of Education and Training
High school student Lucy Hartley gets a 
chance to experience hands on lab work.
 Education & Training Fast Facts
 14 Rotating & full-time graduate students
6 Research fellows
40 Academic interns, over:
13 labs & research areas
5 International visiting scholars
3 Maine Medical Center residents
5 Student employees
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MMCRI is already one of the most innovative research 
organizations in the nation.
 
With your help, we can achieve even more.
By donating to MMCRI, you help bring the latest scientific 
discoveries to the bedside and improve the quality of care patients 
receive. Today’s groundbreaking study could be tomorrow’s life-
saving treatment. Your gift will help support research projects that 
further our understanding of disease processes, which enables us 
to develop better diagnostics and treatment. 
Areas of opportunity for support of our laboratory-based or clinical research projects include: Cardiovascular 
Disease, Cancer, Bone and Mineral Disease, Molecular Biology and Genetics, Clinical Trials, Psychiatric Research, 
and Vector Borne Diseases.
 
Our efforts go beyond research, as well: by supporting our summer scholarships, you will help us educate and cultivate 
the next generation of researchers, and ensure that the quest for knowledge and insight continues for years to come. 
 
If you’re interested in supporting the work of Maine Medical Center Research Institute, please contact 
Kristen Crean of the Philanthropy Department at (207) 662-3895 or by email at kcrean@mmc.org.
Support 
Our Research
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